Loading
A phase 1/2 trial of [18F]FPyQCP in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications is a phase 1/2 interventional study registered as NCT07432633 by Blue Earth Diagnostics, with 71 participants planned, started 2026-02-19 and due to reach its primary completion in 2028-01-31. Interventions recorded: [18F]FPyQCP.
Shares Blue Earth Diagnostics (Bracco), Medpace, Gastric & gastro-oesophageal junction cancer, Ovarian cancer and the tag pipeline.
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Medpace and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Blue Earth Diagnostics (Bracco) and the tag pipeline.